Print
Melissa Geller, MD, FACOG
Melissa Geller, MD, FACOG
Request Appointment
Gynecologic Cancer Clinic
Phillips-Wangensteen Building
First Floor, Clinic 1C
516 Delaware St. SE
Minneapolis, MN 55455
612-626-3444
 

Medical Title:

Academic Appointments:

Services:

Specialties:

Clinical Interests:

Languages Spoken:

Education:

Board Certifications:

"Best Doctors for Women" Minnesota Monthly Magazine 2013

Best Doctors in America, 2009-2010

Minneapolis/St. Paul Magazine Top Doctors, 2009

Geller MA, Argenta P, Bradley W, Dusenbery KE, Brooker D, Downs LS Jr, Judson PL, Carson LF, Boente MP. Treatment and recurrence patterns in endometrial stromal sarcomas and the relation to c-kit expression. Gynecol Oncol. 2004 Dec; 95(3):632-6. PMID: 15581975

Ramakrishnan S, Subramanian IV, Yokoyama Y, Geller M. Angiogenesis in normal and neoplastic ovaries. Angiogenesis. 2005 Oct; 8(2):169-82. PMID: 16211363

Leath CA III, Huh WK, Hyde J Jr, Cohn DE, Resnick KE, Taylor NP, Powell MA, Mutch DG, Bradley WH, Geller MA, Argenta PA, Gold MA. A multi-institutional review of outcomes of endometrial stromal sarcoma. Gynecol Oncol. 2007 Jun; 105(3):630-4.PMID: 17320937

Tan A, Argenta P, Ramirez R, Bliss R, Geller M. The use of sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier in gynecologic malignancies: A retrospective review of outcomes. Ann Surg Oncol. 2009 Feb; 16(2):499-505.PMID: 19018596

Geller MA, Argenta PA, Thomas SG, Dusenbery KE, Judson PL, Boente MP. Feasibility and morbidity of using saline filled tissue Expanders to reduce radiation-induced bowel injury in patients with gynecologic malignancies. Eur J Obstet Gynecol Reprod Biol. 2009 Apr; 143(2):93-7.PMID: 19195764

Geller MA, Ivy J, Dusenbery KE, Ghebre R, Isaksson Vogel R, Argenta PA. A single institution experience using sequential multi-modality adjuvant chemotherapy and radiation in the “sandwich” method for high risk endometrial carcinoma. Gynecol Oncol. 2010 Jul; 118(1):19-23.PMID: 20381136

Geller MA, Bui-Nguyen TM, Rogers LM, Ramakrishnan S. Chemotherapy induces macrophage chemoattractant protein-1 production in ovarian cancer. Int J Gynecol Cancer. 2010 Aug; 20(6):918-25.PMID: 20683396

Geller MA, Downs LS, Judson PL, Ghebre R, Argenta PA, Carson LF, Jonson AL, Godfrey K, Vogel RI, Petzel SV. Learning about ovarian cancer at the time of diagnosis: Video versus usual care. Gynecol Oncol. 2010 Jul; 119:370-5.PMID: 20673972

Geller MA, Cooley S, Argenta PA, Downs LS , Carson LF, Judson PL, Ghebre R, Weigel B, Panoskaltsis-Mortari A, Curtsinger J, Miller JS. Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers. Cancer Immunol Immunother. 2010 Sep 5 [Epub ahead of print] PMID: 20820775

Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA, Jonson AL, Panoskaltsis-Mortari A, Curtsinger J, McKenna D, Dusenbery K, Bliss R, Downs LS, Miller JS. A Phase II study of allogeneic natural killer cells therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy. 2010 Sep 20 [Epub ahead of print]. PMID: 20849361

 
 Visit Other Fairview Sites 
 
 
(c) 2012 Fairview Health Services. All rights reserved.